Safety and Tolerability of EO2002

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Cataract, Endothelial Cell Loss, Corneal

In brief

The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.

Key facts

Study ID

NCT05587205

Run by

Asociación para Evitar la Ceguera en México

People needed

32

Starts

2022-08-30

Expected to finish

2026-10-06

Last updated by the study team

2025-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• All ocular criteria apply to study eye unless otherwise noted.
• Other corneal disease
• Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.
• Descemet membrane detachment.
• History of uveitis or other ocular inflammatory disease.
• History of incisional glaucoma surgery
• Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.
• History of ocular neoplasm.
• ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20/200).
• Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.
• Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.
• Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.

Where it is running

• Asociacion para Evitar la Ceguera en Mexico — Mexico City, Mexico City, Mexico (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.